Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Notes Payables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Notes Payables for 3 consecutive years, with $136396.0 as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables fell 48.93% to $136396.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $136396.0, a 48.93% decrease, with the full-year FY2024 number at $171669.0, changed N/A from a year prior.
  • Notes Payables was $136396.0 for Q3 2025 at bioAffinity Technologies, up from $32946.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $325000.0 in Q3 2022 to a low of $4106.0 in Q2 2024.
  • A 3-year average of $130831.2 and a median of $120581.0 in 2025 define the central range for Notes Payables.
  • Biggest YoY gain for Notes Payables was 2135.72% in 2025; the steepest drop was 48.93% in 2025.
  • bioAffinity Technologies' Notes Payables stood at $325000.0 in 2022, then tumbled by 47.18% to $171669.0 in 2024, then dropped by 20.55% to $136396.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Notes Payables are $136396.0 (Q3 2025), $32946.0 (Q2 2025), and $104766.0 (Q1 2025).